Alpha 1 acid glycoprotein (AGP) binds to STI571 and substantially alters its pharmacokinetics in chronic myeloid leukemia (CML) patients.

被引：0
|
作者：
Gambacorti-Passeri, C
Zucchetti, M
Frapolli, R
Russo, D
Rossi, F
Pogliani, E
Corneo, G
Tornaghi, L
Alberti, D
D'Incalci, M
机构：
[1] NCI, Milan, Italy
[2] Osped San Gerardo, Monza, Italy
[3] Mario Negri Inst Pharmacol Res, Milan, Italy
[4] Univ Udine, I-33100 Udine, Italy
[5] Novards Italia, Origgio, Italy
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1305
引用
收藏
页码：309A / 309A
页数：1
相关论文
共 50 条
  • [21] The effect of Gleevec (STI571;imatinib mesylate) in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) with secondary chromosomal aberrations.
    Mohamed, AN
    Pemberton, P
    Zonder, JA
    Homisha, S
    Ford, J
    Schiffer, CA
    BLOOD, 2001, 98 (11) : 560A - 560A
  • [22] Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia
    Legros, L
    Bourcier, C
    Jacquel, A
    Mahon, FX
    Cassuto, JP
    Auberger, P
    Pagès, G
    BLOOD, 2004, 104 (02) : 495 - 501
  • [23] Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis
    Kaneta, Y
    Kagami, Y
    Katagiri, T
    Tsunoda, T
    Jin-nai, I
    Taguchi, H
    Hirai, H
    Ohnishi, K
    Ueda, T
    Emi, N
    Tomida, A
    Tsuruo, T
    Nakamura, Y
    Ohno, R
    JAPANESE JOURNAL OF CANCER RESEARCH, 2002, 93 (08): : 849 - 856
  • [24] Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response to STI571 in chronic phase CML patients.
    Merx, K
    Kreil, S
    Lahaye, T
    Müller, MC
    Paschka, P
    Schoch, C
    Weisser, A
    Kuhn, C
    Landmann, T
    Gschaidmeier, H
    Berger, U
    Hehlmann, R
    Hochhaus, A
    BLOOD, 2001, 98 (11) : 846A - 847A
  • [25] Imatinib mesylate (STI571) therapy of Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase (Ph plus CML early CP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Rios, MB
    Shan, J
    Hayes, K
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 137A - 137A
  • [26] STI571 administered to chronic myeloid leukemia (CML) patients inhibits cell proliferation, induces apoptosis and initially causes partial inhibition of BCR/ABL autophosphorylation.
    Gambacorti-Passerini, C
    Verga, M
    Rossi, F
    Tornaghi, L
    Bungaro, S
    Ruchatz, H
    Rossi, F
    Pioltelli, P
    Pogliani, E
    Garattini, E
    Capdeville, R
    D'Incalci, M
    Corneo, G
    BLOOD, 2000, 96 (11) : 345A - 345A
  • [27] Imatinib mesylate (STI571) in patients with chronic myeloid leukemia in chronic phase previously submitted to autologous stem cell transplantation.
    Cervantes, F
    Hernández-Boluda, JC
    Odriozola, J
    Camós, M
    Villalón, L
    Martínez-Climent, JA
    del Campo, R
    García-Conde, J
    Montserrat, E
    BLOOD, 2002, 100 (11) : 318B - 318B
  • [28] Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
    Graham, SM
    Jorgensen, HG
    Allan, E
    Pearson, C
    Alcorn, MJ
    Richmond, L
    Holyoake, TL
    BLOOD, 2002, 99 (01) : 319 - 325
  • [29] A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase.
    Talpaz, M
    Silver, RT
    Druker, B
    Paquette, R
    Goldman, JM
    Reese, SF
    Capdeville, R
    BLOOD, 2000, 96 (11) : 469A - 469A
  • [30] Imatinib (Gleevec™, STI571) in patients with chronic myeloid leukemia in myeloid blast crisis (CML-BC):: Up to 36 months follow-up of a phase II study.
    Sawyers, CL
    Hochhaus, A
    Feldman, EJ
    Goldman, JM
    Miller, CB
    Ottmann, OG
    Schiffer, CA
    Talpaz, M
    Guilhot, F
    Deininger, MW
    Fischer, T
    O'Brien, SG
    Stone, RM
    Corneo, G
    Tura, S
    Van Hoomissen, IC
    Gathmann, I
    Druker, BJ
    BLOOD, 2002, 100 (11) : 163A - 164A
12345